Mink therapeutics reports third quarter 2023 results

New york, nov. 09, 2023 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the third quarter 2023. mink executives will host a conference call and webcast at 8:30 a.m. et to discuss the results and to provide a corporate update.
INKT Ratings Summary
INKT Quant Ranking